CRISPR Therapeutics (CRSP) In-Depth Stock Report

Every headline number this report produces, collected in one place before the analysis that derives them. All figures are computed live at page load, so this block reflects the market as of the moment you opened the page.

CRISPR Therapeutics is a gene-editing biotechnology company whose lead product, Casgevy, is an ex vivo CRISPR-engineered cell therapy for sickle cell disease and transfusion-dependent beta thalassemia, developed and commercialized in partnership with Vertex Pharmaceuticals under a profit- and cost-sharing arrangement, with the FDA having expanded its approved use to include younger pediatric patients.

Casgevy works by editing a patient's own hematopoietic stem cells outside the body (the "ex vivo" approach) before reinfusing them, replacing the function of the faulty gene responsible for the underlying disease — a landmark one-time treatment approach, though one that requires a complex, multi-step treatment process involving stem-cell collection, conditioning chemotherapy, and reinfusion.

Beyond Casgevy, CRISPR Therapeutics has been expanding its pipeline into in vivo gene-editing approaches — therapies designed to edit genes directly inside the patient's body rather than requiring cell extraction and reinfusion — including early-stage programs targeting conditions such as refractory hypertension and alpha-1 antitrypsin deficiency, representing a potentially much larger addressable-patient opportunity if successful, given the simpler treatment logistics of an in vivo approach relative to ex vivo cell therapy.

As a still-early-commercial-stage biotechnology company, CRISPR Therapeutics' investment case depends heavily on the pace of Casgevy patient uptake (which has been gradual given the complexity of the treatment process), continued execution on its in vivo pipeline, and the company's cash runway to fund pipeline development before achieving sustained profitability.

This report walks through CRISPR Therapeutics' live valuation across seven independent methods, its proprietary AI Score, a blended analyst price target, and a 5-year Monte Carlo simulation built from its own price history — then lays out the bull case, bear case, and the specific catalysts and risks most likely to move the stock, with particular attention to Casgevy uptake and in vivo pipeline milestones.

Beyond the valuation dashboard, this report examines the Vertex partnership structure, the ex vivo versus in vivo pipeline distinction, competitive positioning within the gene-editing field, and closes with a glossary so readers newer to gene-editing biotech investing can follow the methodology sections without outside references.

The broader competitive and macro environment CRSP operates in — context a pure valuation table can't convey on its own.

Gene editing represents one of the most significant recent advances in biotechnology, with CRISPR-based technology enabling precise modification of DNA sequences to correct or disrupt disease-causing genetic mutations, an approach that has moved from laboratory research to approved commercial medicines within roughly a decade.

The field is broadly divided between ex vivo approaches (editing cells outside the body before reinfusion, as with Casgevy) and in vivo approaches (editing genes directly inside the patient), with in vivo approaches generally viewed as having a larger long-term commercial opportunity given simpler treatment logistics, but also carrying more technical and safety challenges around delivering editing machinery precisely to target tissues inside a living patient.

Gene-editing therapies for rare and genetic diseases have generally commanded very high per-patient prices reflecting their one-time, potentially curative treatment profile, but uptake for approved therapies including Casgevy has in some cases been slower than initial expectations, given the complexity of the treatment process and the need for specialized treatment centers.

The broader biotechnology industry, including gene-editing companies, remains sensitive to the cost and availability of capital for funding clinical development, since most gene-editing companies are not yet consistently profitable and depend on equity or partnership funding to advance their pipelines.

Pulled live from BriMindInvest's market-data pipeline at page load — the same feed that powers /analysis/CRSP. Fields the pipeline doesn't return this load are omitted rather than shown blank.

CRISPR Therapeutics' lead commercial product, Casgevy, is developed and commercialized in partnership with Vertex Pharmaceuticals, with the companies splitting costs and profits under an agreement that gives CRISPR Therapeutics exposure to Casgevy's commercial trajectory without bearing the full commercialization cost and infrastructure burden alone.

The company's broader pipeline includes both additional ex vivo, cell-based programs and a growing set of in vivo gene-editing programs targeting a range of diseases beyond the initial hemoglobinopathy indications Casgevy addresses, reflecting a strategy of leveraging its core CRISPR gene-editing platform across multiple therapeutic modalities and disease areas.

As a clinical- and early-commercial-stage biotechnology company, CRISPR Therapeutics' near-term financial profile is shaped heavily by R&D investment in its pipeline, milestone and profit-sharing payments related to Casgevy, and the company's cash position and runway to fund continued pipeline development.

A closer look at each reporting segment individually, rather than treating the business as a single undifferentiated revenue line.

How management has historically chosen to deploy cash — buybacks, dividends, R&D, and acquisitions — and what that reveals about capital discipline.

As a clinical- and early-commercial-stage biotechnology company, CRISPR Therapeutics' primary capital-allocation priority is funding R&D across its ex vivo and in vivo pipeline programs, alongside its share of Casgevy commercialization costs under the Vertex partnership.

The company's cash position and runway are important considerations for investors, since continued pipeline development before achieving sustained profitability from Casgevy and future products will likely require careful cash management and, potentially, additional financing.

Prospective investors should review CRISPR Therapeutics' most recent 10-Q and earnings-call commentary for the current specific cash position, quarterly cash-burn rate, and updated runway guidance, since these figures evolve quickly for a company at this stage.

Leadership, incentive alignment, and governance structure — factors that shape execution risk independent of the underlying business model.

CRISPR Therapeutics is led by Chairman and CEO Samarth Kulkarni, who has overseen the company's progression from a gene-editing research platform through Casgevy's approval and commercial launch.

Prospective investors should review CRISPR Therapeutics' proxy statement for the specifics of current board composition, executive compensation structure, and insider ownership, since these details are disclosed by the company and change annually.

In-depth reports for other names in CRISPR Therapeutics's comparable set.

Specific, falsifiable triggers — not vague sentiment — that would move us toward or away from the bull case above.

CRISPR Therapeutics competes with other gene-editing and cell-therapy companies pursuing hemoglobinopathy and other genetic-disease treatments, though Casgevy's status as one of the first approved CRISPR-based medicines gives the company an early leadership position and real-world commercial and manufacturing experience that newer entrants lack.

In the broader gene-editing field, competitors are pursuing a range of editing technologies and delivery approaches (including base editing and prime editing, variations on CRISPR technology), meaning the competitive landscape extends beyond companies using the exact same editing modality.

Vertex Pharmaceuticals, while a commercialization partner for Casgevy, is also a large, diversified biopharmaceutical company with its own broader pipeline and resources, giving CRISPR Therapeutics a well-resourced partner for Casgevy specifically, even as CRISPR Therapeutics pursues its own independent pipeline beyond that partnership.

Moderna and Regeneron, while not direct gene-editing competitors, represent alternative platform-biotechnology approaches (mRNA and antibody discovery, respectively) that compete for some of the same investor capital allocated to differentiated biotechnology platform companies.

A process for using this report, not a recommendation — how to weigh valuation, scenario spread, and your own risk tolerance.

Why this report is different from asking a general-purpose AI chatbot about the stock.

Plain-English definitions for the terms used throughout this report, for readers newer to equity valuation.